Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa dosing schedules in cancer-associated anemia
NCT00058331Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2003
- Primary completion
- May 2006
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
A Phase 3 trial of epoetin alfa in anemia, sponsored by Cancer and Leukemia Group B. Started Jun 2003; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00058331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058331.